Divi's Laboratories Limited (DIVISLAB) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE361B01024
Key metrics
- Market Cap
- ₹2.42 L Cr
- P/E Ratio
- 93.69
- EPS
- 97.13
- Book Value
- 631.37
- P/B Ratio
- 14.64
- ROE
- 15.32%
- ROCE
- 17.77%
- Debt / Equity
- 0
- Net Margin
- 24.51%
- Revenue Growth
- 12.34%
- Profit Growth
- 17.21%
- Dividend Yield
- 0.32%
- 52W High
- ₹9,467.00
- 52W Low
- ₹5,636.50
- Market Cap Band
- large cap
- Face Value
- 2
Ratios computed from the annual results period ending 2026-03-31.
About Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
- Headquarters
- Hyderabad, India
- Employees
- 11,565
- Promoter Holding
- 51.99%
The full Divi's Laboratories Limited analysis
Create a free account to open the complete DIVISLAB deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.